Published in Toxicon on February 04, 2013
Sensory aspects of movement disorders. Lancet Neurol (2014) 1.09
Engineering enhanced protein disaggregases for neurodegenerative disease. Prion (2015) 0.96
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol (2016) 0.94
Treatment of dystonia. Neurotherapeutics (2014) 0.91
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
On botulinum neurotoxin variability. MBio (2015) 0.87
Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol (2014) 0.82
Detection of the motor points of the abdominal muscles. Eur J Appl Physiol (2014) 0.81
Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. J Neural Transm (Vienna) (2014) 0.80
The first non Clostridial botulinum-like toxin cleaves VAMP within the juxtamembrane domain. Sci Rep (2016) 0.79
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol (2014) 0.78
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A. Patient Prefer Adherence (2015) 0.77
Hemifacial spasm and neurovascular compression. ScientificWorldJournal (2014) 0.77
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther (2015) 0.77
Update on treatments for dystonia. Curr Neurol Neurosci Rep (2014) 0.77
Focal task specific dystonia: a review and update. J Neurol (2016) 0.77
Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm. Tremor Other Hyperkinet Mov (N Y) (2015) 0.76
Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia. Springerplus (2016) 0.75
Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry. Mov Disord Clin Pract (2015) 0.75
Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Prefer Adherence (2016) 0.75
Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord (2015) 0.75
Reduced Neck Muscle Strength and Altered Muscle Mechanical Properties in Cervical Dystonia Following Botulinum Neurotoxin Injections: A Prospective Study. J Mov Disord (2016) 0.75
History of Botulinum Toxin Treatment in Movement Disorders. Tremor Other Hyperkinet Mov (N Y) (2016) 0.75
Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study. Tremor Other Hyperkinet Mov (N Y) (2016) 0.75
Septins: Regulators of Protein Stability. Front Cell Dev Biol (2016) 0.75
Deep Brain Stimulation: Expanding Applications. Neurol Med Chir (Tokyo) (2015) 0.75
Treatment of Blepharospasm/Hemifacial Spasm. Curr Treat Options Neurol (2017) 0.75
Botulinum neurotoxin A1 likes it double sweet. Nat Struct Mol Biol (2016) 0.75
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Transportin-SR2 imports HIV into the nucleus. Curr Biol (2008) 2.35
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol (2004) 2.30
Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol (2003) 2.28
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Age and cigarette smoking are independently associated with the cutaneous vascular response to local warming. Microcirculation (2009) 2.05
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res (2012) 1.90
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis (2007) 1.79
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet (2005) 1.71
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Robust crop resistance to broadleaf and grass herbicides provided by aryloxyalkanoate dioxygenase transgenes. Proc Natl Acad Sci U S A (2010) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain (2010) 1.66
Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery (2002) 1.65
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol (2011) 1.62
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Ann Neurol (2004) 1.51
Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol (2002) 1.51
A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Arch Neurol (2003) 1.49
Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab (2005) 1.48
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Pathological gambling in Parkinson's disease: subthalamic oscillations during economics decisions. Mov Disord (2013) 1.45
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Hypnosis for treatment of HIV neuropathic pain: a preliminary report. Pain Med (2013) 1.44
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Weight gain in the treatment of mood disorders. J Clin Psychiatry (2003) 1.42
Determination of the Boltzmann constant using a quasi-spherical acoustic resonator. Philos Trans A Math Phys Eng Sci (2011) 1.41
Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage (2004) 1.40
Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol (2012) 1.39
AIDS and AIDS-treatment neuropathies. Curr Pain Headache Rep (2002) 1.39
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics (2010) 1.33
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals (2011) 1.30
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol (2006) 1.29